ArticleCell reports. Medicine2025
Challenges and opportunities in microRNA-based cancer therapeutics.
Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Dark matter matters: from noncoding RNA regulation to cancer immunity.Oncoimmunology · 2026Review
- Engineering microRNAs as multimodal cancer therapeutics.Molecular therapy. Nucleic acids · 2026Article
- Development of gemcitabine-modified multimodal miR-129 mimic as a novel therapeutic in non-small cell lung cancer.Molecular therapy. Nucleic acids · 2026Article
- Adipose stem cells derived extracellular vesicles alleviate retinal excitotoxicity via miR-23a-5p/PLCD1/PKCA/GluA2 axis: a potential therapeutic strategy.Stem cell research & therapy · 2026Article
- Emerging role of microRNAs as modulators of the tumor immune microenvironment.Journal for immunotherapy of cancer · 2026Review
- MicroRNAs in Pediatric Primary Hypertension: Promising Biomarkers or Context-Dependent Regulators?-A Narrative Review.Biomolecules · 2026Review
- Deciphering the cancer chemopreventive potential of phytochemicals: an integrative perspective on molecular targets and signaling networks.Cancer cell international · 2026Review
- Article
- Review
- MicroRNAs as Emerging Therapeutic Targets Modulating the Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma.International journal of molecular sciences · 2025Review
- MicroRNA bioinformatics in precision oncology: an integrated pipeline from NGS to AI-based target discovery.Journal of applied genetics · 2025Review
- The Role of MCM7 and Its Hosted miR-106b-25 Cluster in Renal Cancer Progression.International journal of molecular sciences · 2025Article
- MicroRNA-mediated regulation of autophagy in lung cancer: role in tumourigenesis and chemotherapy resistance.Academia oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 2024 Nobel Prize honored groundbreaking microRNA (miRNA) discoveries that unveiled the critical functions of miRNAs in fundamental biology and human health. Despite promising therapeutic potential, there are no Food and Drug Administration (FDA)-approved miRNA-based cancer therapies. This commentary discusses the progress and challenges of miRNA-based cancer therapeutics and their potential impact on future clinical oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.